$HAREHOLDER NOTICE: M&A Class Action Firm Launches Investigation into Exact Sciences Corporation (NASDAQ: EXAS)
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 20 2025
0mins
Should l Buy EXAS?
Source: Globenewswire
Class Action Firm Recognition: Monteverde & Associates PC, led by attorney Juan Monteverde, is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report and has successfully recovered millions for shareholders.
Investigation of Exact Sciences: The firm is currently investigating Exact Sciences Corporation regarding its proposed sale to Abbott Laboratories, where shareholders are expected to receive $105.00 per share.
Free Consultation Offer: Monteverde & Associates offers free consultations for shareholders concerned about the transaction, emphasizing that there is no cost or obligation involved.
Firm's Track Record: The firm, based in the Empire State Building, has a strong history of litigating and recovering funds for shareholders, including cases in trial and appellate courts up to the U.S. Supreme Court.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy EXAS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on EXAS
Wall Street analysts forecast EXAS stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for EXAS is 100.20 USD with a low forecast of 78.00 USD and a high forecast of 105.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
20 Analyst Rating
1 Buy
19 Hold
0 Sell
Hold
Current: 102.660
Low
78.00
Averages
100.20
High
105.00
Current: 102.660
Low
78.00
Averages
100.20
High
105.00
About EXAS
Exact Sciences Corporation is a provider of cancer screening and diagnostic tests. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. It is focusing its research and development efforts on three main areas: Colorectal Cancer Screening Test Development, MCED Test Development and MRD Test Development. Its products and services include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, OncoExTra Test, and Riskguard Test. Its flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patient’s breast tumor tissue.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Hims & Hers Introduces New Cancer Test, But It Might Not Be Fully Prepared for Use.
Super Bowl Ad Controversy: Hims & Hers has released a new Super Bowl ad that is raising concerns among medical experts.
Promotion of Medical Products: The ad promotes the company's weight loss drugs, testosterone treatments, and a controversial early cancer detection test.
See More
Exact Sciences' Sale to Abbott Clears HSR Waiting Period
- Transaction Progress: Exact Sciences (EXAS) shares rose 0.5% as reports confirmed that the HSR waiting period for its $21 billion all-cash acquisition by Abbott Laboratories (ABT) expired on Thursday, indicating the deal has cleared antitrust scrutiny and boosting market confidence in its success.
- Market Reaction: Following the news, Abbott (ABT) shares also increased by 0.5%, reflecting investor optimism regarding the acquisition, which is expected to enhance Abbott's market share and growth in the cancer screening sector.
- Deal Background: Abbott announced the acquisition of Exact Sciences last November, valuing the deal at $105 per share, aimed at strengthening its competitive position in the cancer screening market, aligning with its long-term growth strategy.
- Investor Interest: Although Exact Sciences and Abbott did not immediately respond to media inquiries, the positive sentiment surrounding the deal may attract more investor attention, particularly regarding technological innovations and market potential in the cancer screening field.
See More
Investor Rights Law Firm Investigates Multiple Companies for Securities Violations
- SkyWater Transaction Investigation: Halper Sadeh LLC is investigating SkyWater Technology, Inc.'s sale to IonQ for $15 in cash and $20 in IonQ common stock, potentially violating fiduciary duties to shareholders, which could impact shareholder rights.
- Exact Sciences Transaction Review: The sale of Exact Sciences Corporation to Abbott for $105 per common share in cash is under scrutiny by Halper Sadeh LLC for compliance with federal securities laws, potentially affecting shareholder rights and options.
- Gold Resource Transaction Analysis: Gold Resource Corporation's sale to Goldgroup Mining Inc. involves an exchange of 1.4476 common shares of Goldgroup for each share of Gold Resource, with Halper Sadeh LLC assessing the transaction's implications for shareholder rights and protections.
- Movano Merger Investigation: The merger of Movano Inc. with Corvex, Inc. will result in Movano shareholders owning approximately 3.8% of the combined company, prompting Halper Sadeh LLC to investigate the legality and impact of this transaction on shareholder interests.
See More
Exact Sciences Celebrates Passage of Landmark Cancer Detection Legislation
- Legislation Passed: The passage of the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act establishes a pathway for Medicare coverage of multi-cancer early detection (MCED) tests, expected to benefit millions of seniors and significantly enhance access to early cancer detection.
- Cancer Detection Technology: Exact Sciences' Cancerguard® test is designed to detect multiple cancers through a simple blood draw, with modeling suggesting that this technology could reduce stage IV cancer diagnoses by 45%, thereby improving early detection rates and patient outcomes.
- Policy Support: The legislation has garnered overwhelming bipartisan support, reflecting the growing recognition of the urgent need for early cancer detection, marking an effective alignment of public policy with scientific innovation to promote the adoption of cancer screening technologies.
- Social Impact: Exact Sciences CEO Kevin Conroy stated that this legislation will bring hope to countless patients by enabling earlier cancer detection, allowing them more opportunities to celebrate important moments with loved ones, demonstrating the company's commitment to improving patient quality of life.
See More
Passage of MCED Legislation Marks Milestone for Early Cancer Detection
- Legislative Milestone: Exact Sciences celebrates the passage of federal legislation that establishes a pathway for Medicare coverage of multi-cancer early detection (MCED) tests, which is expected to significantly enhance detection opportunities for Medicare beneficiaries, addressing the urgent need for screening in nearly 70% of annual cancer cases without recommended tests in the U.S.
- Technological Potential: The MCED tests will receive a clear coverage framework following FDA approval based on the Nancy Gardner Sewell Act, with modeling suggesting a potential 45% reduction in stage IV cancer diagnoses, thereby improving early diagnosis and treatment opportunities for patients.
- Public Support: The legislation has garnered overwhelming bipartisan support, reflecting a growing recognition of the urgent need for early cancer detection, with Exact Sciences CEO Kevin Conroy stating that this will bring hope to countless patients, allowing them to celebrate more precious moments with loved ones.
- Innovative Testing: Exact Sciences' Cancerguard® test aims to detect multiple cancers through a simple blood draw, and while it has not yet received FDA approval, its high specificity and broad detection capabilities will provide a crucial complement to future cancer screening efforts.
See More
Oncotype DX Test Surpasses 2 Million Patients Worldwide
- Global Standard Established: The Oncotype DX Breast Recurrence Score test has now guided treatment decisions for over 2 million breast cancer patients worldwide, underscoring its critical role in personalized treatment and solidifying its status as a global standard of care.
- Economic Benefits of Avoiding Chemotherapy: The test has enabled approximately 1.6 million patients to safely avoid potentially unnecessary chemotherapy, with an estimated average lifetime savings of about $10,000 per patient in the U.S. healthcare system, significantly reducing overall medical costs.
- Clinical Validation and Broad Application: The Oncotype DX test is utilized in over 100 countries and has been validated in numerous landmark clinical trials, ensuring equitable access for diverse populations and enhancing its authority in clinical practice guidelines.
- Advancement of Personalized Treatment: This test not only predicts chemotherapy benefit but also integrates with clinical and pathological factors to provide deeper insights, aiding physicians in making more precise treatment decisions and advancing the personalization of breast cancer care.
See More
Hims & Hers Introduces New Cancer Test, But It Might Not Be Fully Prepared for Use.
Super Bowl Ad Controversy: Hims & Hers has released a new Super Bowl ad that is raising concerns among medical experts.
Promotion of Medical Products: The ad promotes the company's weight loss drugs, testosterone treatments, and a controversial early cancer detection test.
See More
Exact Sciences' Sale to Abbott Clears HSR Waiting Period
- Transaction Progress: Exact Sciences (EXAS) shares rose 0.5% as reports confirmed that the HSR waiting period for its $21 billion all-cash acquisition by Abbott Laboratories (ABT) expired on Thursday, indicating the deal has cleared antitrust scrutiny and boosting market confidence in its success.
- Market Reaction: Following the news, Abbott (ABT) shares also increased by 0.5%, reflecting investor optimism regarding the acquisition, which is expected to enhance Abbott's market share and growth in the cancer screening sector.
- Deal Background: Abbott announced the acquisition of Exact Sciences last November, valuing the deal at $105 per share, aimed at strengthening its competitive position in the cancer screening market, aligning with its long-term growth strategy.
- Investor Interest: Although Exact Sciences and Abbott did not immediately respond to media inquiries, the positive sentiment surrounding the deal may attract more investor attention, particularly regarding technological innovations and market potential in the cancer screening field.
See More
Investor Rights Law Firm Investigates Multiple Companies for Securities Violations
- SkyWater Transaction Investigation: Halper Sadeh LLC is investigating SkyWater Technology, Inc.'s sale to IonQ for $15 in cash and $20 in IonQ common stock, potentially violating fiduciary duties to shareholders, which could impact shareholder rights.
- Exact Sciences Transaction Review: The sale of Exact Sciences Corporation to Abbott for $105 per common share in cash is under scrutiny by Halper Sadeh LLC for compliance with federal securities laws, potentially affecting shareholder rights and options.
- Gold Resource Transaction Analysis: Gold Resource Corporation's sale to Goldgroup Mining Inc. involves an exchange of 1.4476 common shares of Goldgroup for each share of Gold Resource, with Halper Sadeh LLC assessing the transaction's implications for shareholder rights and protections.
- Movano Merger Investigation: The merger of Movano Inc. with Corvex, Inc. will result in Movano shareholders owning approximately 3.8% of the combined company, prompting Halper Sadeh LLC to investigate the legality and impact of this transaction on shareholder interests.
See More
Exact Sciences Celebrates Passage of Landmark Cancer Detection Legislation
- Legislation Passed: The passage of the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act establishes a pathway for Medicare coverage of multi-cancer early detection (MCED) tests, expected to benefit millions of seniors and significantly enhance access to early cancer detection.
- Cancer Detection Technology: Exact Sciences' Cancerguard® test is designed to detect multiple cancers through a simple blood draw, with modeling suggesting that this technology could reduce stage IV cancer diagnoses by 45%, thereby improving early detection rates and patient outcomes.
- Policy Support: The legislation has garnered overwhelming bipartisan support, reflecting the growing recognition of the urgent need for early cancer detection, marking an effective alignment of public policy with scientific innovation to promote the adoption of cancer screening technologies.
- Social Impact: Exact Sciences CEO Kevin Conroy stated that this legislation will bring hope to countless patients by enabling earlier cancer detection, allowing them more opportunities to celebrate important moments with loved ones, demonstrating the company's commitment to improving patient quality of life.
See More
Passage of MCED Legislation Marks Milestone for Early Cancer Detection
- Legislative Milestone: Exact Sciences celebrates the passage of federal legislation that establishes a pathway for Medicare coverage of multi-cancer early detection (MCED) tests, which is expected to significantly enhance detection opportunities for Medicare beneficiaries, addressing the urgent need for screening in nearly 70% of annual cancer cases without recommended tests in the U.S.
- Technological Potential: The MCED tests will receive a clear coverage framework following FDA approval based on the Nancy Gardner Sewell Act, with modeling suggesting a potential 45% reduction in stage IV cancer diagnoses, thereby improving early diagnosis and treatment opportunities for patients.
- Public Support: The legislation has garnered overwhelming bipartisan support, reflecting a growing recognition of the urgent need for early cancer detection, with Exact Sciences CEO Kevin Conroy stating that this will bring hope to countless patients, allowing them to celebrate more precious moments with loved ones.
- Innovative Testing: Exact Sciences' Cancerguard® test aims to detect multiple cancers through a simple blood draw, and while it has not yet received FDA approval, its high specificity and broad detection capabilities will provide a crucial complement to future cancer screening efforts.
See More
Oncotype DX Test Surpasses 2 Million Patients Worldwide
- Global Standard Established: The Oncotype DX Breast Recurrence Score test has now guided treatment decisions for over 2 million breast cancer patients worldwide, underscoring its critical role in personalized treatment and solidifying its status as a global standard of care.
- Economic Benefits of Avoiding Chemotherapy: The test has enabled approximately 1.6 million patients to safely avoid potentially unnecessary chemotherapy, with an estimated average lifetime savings of about $10,000 per patient in the U.S. healthcare system, significantly reducing overall medical costs.
- Clinical Validation and Broad Application: The Oncotype DX test is utilized in over 100 countries and has been validated in numerous landmark clinical trials, ensuring equitable access for diverse populations and enhancing its authority in clinical practice guidelines.
- Advancement of Personalized Treatment: This test not only predicts chemotherapy benefit but also integrates with clinical and pathological factors to provide deeper insights, aiding physicians in making more precise treatment decisions and advancing the personalization of breast cancer care.
See More
